Table 2.

The association between immune activation marker levels and cHL by EBV statusa

≤1 year prior to diagnosis
EBV+ casesEBV casesEBV+ vs. EBV cases
MarkerbCase/controlOR (95% CI)cCase/controlOR (95% CI)EBV+/EBVOR (95% CI)
sCD3012/242.03 (1.10–4.05)53/1063.15 (2.09–4.92)12/530.95 (0.67–1.46)
IL612/236.48 (2.45–26.67)53/1041.90 (1.47–2.54)12/530.96 (0.66–1.35)
IgE12/241.06 (0.83–1.38)52/1041.16 (1.02–1.34)12/520.93 (0.75–1.17)
IL1012/241.55 (0.93–2.63)53/1061.06 (0.61–1.74)12/533.10 (1.73–6.05)
>1 year prior to diagnosis
EBV+ casesEBV casesEBV+ vs. EBV cases
MarkerCase/controlOR (95% CI)Case/controlOR (95% CI)EBV+/EBVOR (95% CI)
sCD3018/362.00 (1.07–4.14)58/1163.41 (2.18–5.52)18/581.06 (0.70–1.77)
IL617/361.60 (1.03–2.63)58/1161.06 (0.82–1.37)17/581.14 (0.78–1.68)
IgE18/360.97 (0.76–1.23)58/1151.15 (1.02–1.32)18/581.02 (0.83–1.27)
IL1018/361.24 (0.81–1.89)58/1161.02 (0.59–1.67)18/582.16 (1.28–3.97)
  • aAdjusted for the matching factors (age, sex, race/ethnicity, serum collection date, and number of serum samples).

  • bAnalyses of continuous levels of sCD30, IL6, IgE, and detectable IL10.

  • cOR for association with one unit increase in the immune marker on the natural log scale, or as detectable versus undetectable for IL10.